Equities research analysts expect Incyte Co. (NASDAQ:INCY) to post earnings per share of ($0.12) for the current quarter, Zacks reports. Sixteen analysts have made estimates for Incyte’s earnings. The lowest EPS estimate is ($0.33) and the highest is $0.30. Incyte reported earnings per share of ($0.96) in the same quarter last year, which suggests a positive year-over-year growth rate of 87.5%. The company is expected to announce its next quarterly earnings report on Thursday, May 3rd.
According to Zacks, analysts expect that Incyte will report full-year earnings of ($0.27) per share for the current year, with EPS estimates ranging from ($1.83) to $0.96. For the next year, analysts forecast that the business will report earnings of $0.42 per share, with EPS estimates ranging from ($1.08) to $2.18. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow Incyte.
Incyte (NASDAQ:INCY) last posted its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.54. Incyte had a negative net margin of 20.38% and a negative return on equity of 11.85%. The business had revenue of $444.20 million during the quarter, compared to the consensus estimate of $435.23 million. During the same quarter last year, the firm posted $0.05 EPS. Incyte’s revenue was up 36.0% compared to the same quarter last year.
INCY has been the subject of several research reports. JPMorgan Chase & Co. reissued a “buy” rating on shares of Incyte in a research report on Tuesday, October 31st. BMO Capital Markets lifted their price target on shares of Incyte from $162.00 to $166.00 and gave the company an “outperform” rating in a research report on Tuesday, October 31st. Oppenheimer set a $135.00 price target on shares of Incyte and gave the company a “hold” rating in a research report on Tuesday, October 31st. Royal Bank of Canada reduced their price target on shares of Incyte from $136.00 to $120.00 and set a “sector perform” rating for the company in a research report on Tuesday, November 21st. Finally, ValuEngine downgraded shares of Incyte from a “hold” rating to a “sell” rating in a research report on Wednesday, November 29th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $142.94.
Incyte (NASDAQ:INCY) traded up $2.61 during midday trading on Monday, reaching $87.80. 1,440,106 shares of the company traded hands, compared to its average volume of 1,870,000. Incyte has a twelve month low of $80.85 and a twelve month high of $153.15. The company has a current ratio of 4.01, a quick ratio of 3.99 and a debt-to-equity ratio of 0.01. The firm has a market cap of $19,100.00, a P/E ratio of -56.28 and a beta of 0.59.
In other news, EVP Reid M. Huber sold 1,958 shares of Incyte stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $85.55, for a total transaction of $167,506.90. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider David W. Gryska sold 1,952 shares of Incyte stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $85.56, for a total value of $167,013.12. Following the sale, the insider now owns 12,922 shares in the company, valued at $1,105,606.32. The disclosure for this sale can be found here. Insiders have sold a total of 16,366 shares of company stock worth $1,557,396 over the last quarter. Company insiders own 17.70% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Inverness Counsel LLC NY bought a new stake in shares of Incyte during the 3rd quarter worth $330,000. LMR Partners LLP bought a new stake in shares of Incyte during the 3rd quarter worth $394,000. Exane Derivatives bought a new stake in shares of Incyte during the 4th quarter worth $669,000. Swiss National Bank raised its stake in shares of Incyte by 3.0% during the 3rd quarter. Swiss National Bank now owns 641,700 shares of the biopharmaceutical company’s stock worth $74,912,000 after purchasing an additional 18,700 shares during the period. Finally, Prudential Financial Inc. raised its stake in shares of Incyte by 0.6% during the 3rd quarter. Prudential Financial Inc. now owns 236,699 shares of the biopharmaceutical company’s stock worth $27,633,000 after purchasing an additional 1,490 shares during the period. Institutional investors own 89.43% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Analysts Expect Incyte Co. (INCY) Will Post Earnings of -$0.12 Per Share” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/24/analysts-expect-incyte-co-incy-will-post-earnings-of-0-12-per-share.html.
Incyte Company Profile
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Get a free copy of the Zacks research report on Incyte (INCY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.